MBX Biosciences, a clinical-stage biopharmaceutical company based in Carmel, Indiana, focuses on precision peptide therapies for endocrine and metabolic disorders and went public on September 13, 2024. Its product candidates include MBX 2109, MBX 1416, and MBX 4291, targeting various hormone-related conditions.
MBX Biosciences (MBX) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, MBX Biosciences's actual EPS was -$0.58, beating the estimate of -$0.77 per share, resulting in a 24.42% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
